Table 2 Crude and adjusted odds ratios for the association between variables and the risk of Pneumocystis Pneumonia
Univariable analysis | Multivariable analysis | |||||
|---|---|---|---|---|---|---|
Forced entering | Stepwise selection | |||||
OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | |
Disease duration, incremental year | 0.94 (0.88–1.01) | 0.10 | 1.10 (0.92–1.32) | 0.31 | ||
CCI without moderate to severe renal disease | 1.65 (1.23–2.22) | < 0.01 | 1.51 (0.91–2.49) | 0.12 | ||
Moderate to severe renal disease | 4.97 (2.62–9.42) | < 0.01 | 7.61 (1.80–32.16) | < 0.01 | 6.73 (1.98–22.92) | < 0.01 |
Trimethoprim-sulfamethaxazole | < 0.001 (< 0.001–> 999) | 0.99 | < 0.001 (< 0.001–> 999) | 0.99 | ||
Glucocorticoidsa | ||||||
≤ 5 mg/day | Ref. | Ref. | Ref. | |||
5–10 mg/day | 8.76 (1.75–43.81) | < 0.01 | 23.73 (2.18–258.63) | < 0.01 | 25.88 (2.97–225.33) | < 0.01 |
> 10 mg/day | 90.63 (20.54–399.95) | < 0.01 | 997.90 (51.32–> 999) | < 0.01 | 286.58 (28.58–> 999) | < 0.01 |
Hydroxychloroquine cumulative dose | ||||||
None | Ref. | Ref. | Ref. | |||
≤ 14 gb | 0.56 (0.28–1.14) | 0.11 | 0.56 (0.14–2.26) | 0.41 | 0.69 (0.21–2.24) | 0.54 |
> 14 gb | 0.45 (0.21–0.97) | 0.04 | 0.12 (0.02–0.63) | 0.01 | 0.20 (0.05–0.71) | 0.01 |
Sulfasalazine | 0.85 (0.10–7.20) | 0.88 | 0.08 (0.00–4.71) | 0.22 | ||
Cyclophosphamide cumulative dose | ||||||
None | Ref. | Ref. | Ref. | |||
≤ 1.4 gb | 3.18 (1.17–8.62) | 0.02 | 0.42 (0.08–2.15) | 0.30 | 0.64 (0.14–3.01) | 0.58 |
> 1.4 gb | 21.87 (6.00–79.81) | < 0.01 | 12.01 (1.42–101.58) | 0.02 | 11.52 (1.97–67.39) | < 0.01 |
Methotrexate / Leflunomide | 0.79 (0.17–3.62) | 0.76 | 0.29 (0.01–7.94) | 0.47 | ||
Mycophenolate mofetil/mycophenolic acid | 34.11 (7.65–152.19) | < 0.01 | 38.07 (0.88–> 999) | 0.06 | 50.79 (5.32–484.77) | < 0.01 |
Cyclosporine | 5.03 (2.12–11.92) | < 0.01 | 3.83 (0.64–23.05) | 0.14 | ||
Azathioprine | 1.02 (0.53–1.96) | 0.96 | 0.57 (0.15–2.26) | 0.43 | ||
AIC | 85 | 82 | ||||